Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation

Autores
Brusco, Luis Ignacio; Cruz, Pablo; Cangas, Alicia; González Rojas, Carmen; Vigo, Daniel Eduardo; Cardinali, Daniel Pedro
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The association of sleep disruption with a higher vulnerability to COVID-19 infection is asubject of major clinical importance. In patients with pneumonia associated with COVID-19admitted to non-intensive care unit (NICU) several factors, like the disrupting influence ofrespiratory distress, medication, greater stress due to social isolation, and lack of appropriateexposure to environmental light can be instrumental to disrupt sleep / wake cycle. Thetherapeutic potential of melatonin to counteract the consequences of COVID-19 infection hasbeen advocated. Because of its wide-ranging effects as an antioxidant, anti-inflammatory, andimmunomodulatory compound, melatonin could be unique in impairing the consequences ofSARS-CoV-2 infection. Melatonin is also an effective chronobiotic agent to reverse the circadiandisruption of social isolation and to control delirium in severely affected patients. Properlyadministered, melatonin may restore the optimal circadian pattern of the sleep-wake cycle andimprove clinical condition in pneumonia associated with COVID-19 patients. The present reviewarticle discusses the importance of maintaining normal sleep and circadian rhythmicity in NICUpatients and provides preliminary data suggesting the efficacy of melatonin (9 mg/day) to reducelength of stay of pneumonia patients associated with COVID-19 in NICU.
Fil: Brusco, Luis Ignacio. Universidad de Buenos Aires. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cruz, Pablo. No especifíca;
Fil: Cangas, Alicia. No especifíca;
Fil: González Rojas, Carmen. No especifíca;
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
Materia
CHRONOTHERAPY
COVID-19 PANDEMIC
MELATONIN
PNEUMONIA
RESPIRATORY DISTRESS
SLEEP
COVID-19
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/134834
Acceder
id CONICETDig_7a6236ae1d54b8b3bb0a3f46c73a3881
oai_identifier_str oai:ri.conicet.gov.ar:11336/134834
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulationBrusco, Luis IgnacioCruz, PabloCangas, AliciaGonzález Rojas, CarmenVigo, Daniel EduardoCardinali, Daniel PedroCHRONOTHERAPYCOVID-19 PANDEMICMELATONINPNEUMONIARESPIRATORY DISTRESSSLEEPCOVID-19https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The association of sleep disruption with a higher vulnerability to COVID-19 infection is asubject of major clinical importance. In patients with pneumonia associated with COVID-19admitted to non-intensive care unit (NICU) several factors, like the disrupting influence ofrespiratory distress, medication, greater stress due to social isolation, and lack of appropriateexposure to environmental light can be instrumental to disrupt sleep / wake cycle. Thetherapeutic potential of melatonin to counteract the consequences of COVID-19 infection hasbeen advocated. Because of its wide-ranging effects as an antioxidant, anti-inflammatory, andimmunomodulatory compound, melatonin could be unique in impairing the consequences ofSARS-CoV-2 infection. Melatonin is also an effective chronobiotic agent to reverse the circadiandisruption of social isolation and to control delirium in severely affected patients. Properlyadministered, melatonin may restore the optimal circadian pattern of the sleep-wake cycle andimprove clinical condition in pneumonia associated with COVID-19 patients. The present reviewarticle discusses the importance of maintaining normal sleep and circadian rhythmicity in NICUpatients and provides preliminary data suggesting the efficacy of melatonin (9 mg/day) to reducelength of stay of pneumonia patients associated with COVID-19 in NICU.Fil: Brusco, Luis Ignacio. Universidad de Buenos Aires. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Cruz, Pablo. No especifíca;Fil: Cangas, Alicia. No especifíca;Fil: González Rojas, Carmen. No especifíca;Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; ArgentinaFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; ArgentinaOpen Journal Systems2021-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/134834Brusco, Luis Ignacio; Cruz, Pablo; Cangas, Alicia; González Rojas, Carmen; Vigo, Daniel Eduardo; et al.; Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation; Open Journal Systems; Melatonin Research; 4; 1; 1-2021; 173-1882641-0281CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.32794/mr11250089info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:35:52Zoai:ri.conicet.gov.ar:11336/134834instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:35:52.813CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation
title Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation
spellingShingle Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation
Brusco, Luis Ignacio
CHRONOTHERAPY
COVID-19 PANDEMIC
MELATONIN
PNEUMONIA
RESPIRATORY DISTRESS
SLEEP
COVID-19
title_short Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation
title_full Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation
title_fullStr Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation
title_full_unstemmed Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation
title_sort Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation
dc.creator.none.fl_str_mv Brusco, Luis Ignacio
Cruz, Pablo
Cangas, Alicia
González Rojas, Carmen
Vigo, Daniel Eduardo
Cardinali, Daniel Pedro
author Brusco, Luis Ignacio
author_facet Brusco, Luis Ignacio
Cruz, Pablo
Cangas, Alicia
González Rojas, Carmen
Vigo, Daniel Eduardo
Cardinali, Daniel Pedro
author_role author
author2 Cruz, Pablo
Cangas, Alicia
González Rojas, Carmen
Vigo, Daniel Eduardo
Cardinali, Daniel Pedro
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv CHRONOTHERAPY
COVID-19 PANDEMIC
MELATONIN
PNEUMONIA
RESPIRATORY DISTRESS
SLEEP
COVID-19
topic CHRONOTHERAPY
COVID-19 PANDEMIC
MELATONIN
PNEUMONIA
RESPIRATORY DISTRESS
SLEEP
COVID-19
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The association of sleep disruption with a higher vulnerability to COVID-19 infection is asubject of major clinical importance. In patients with pneumonia associated with COVID-19admitted to non-intensive care unit (NICU) several factors, like the disrupting influence ofrespiratory distress, medication, greater stress due to social isolation, and lack of appropriateexposure to environmental light can be instrumental to disrupt sleep / wake cycle. Thetherapeutic potential of melatonin to counteract the consequences of COVID-19 infection hasbeen advocated. Because of its wide-ranging effects as an antioxidant, anti-inflammatory, andimmunomodulatory compound, melatonin could be unique in impairing the consequences ofSARS-CoV-2 infection. Melatonin is also an effective chronobiotic agent to reverse the circadiandisruption of social isolation and to control delirium in severely affected patients. Properlyadministered, melatonin may restore the optimal circadian pattern of the sleep-wake cycle andimprove clinical condition in pneumonia associated with COVID-19 patients. The present reviewarticle discusses the importance of maintaining normal sleep and circadian rhythmicity in NICUpatients and provides preliminary data suggesting the efficacy of melatonin (9 mg/day) to reducelength of stay of pneumonia patients associated with COVID-19 in NICU.
Fil: Brusco, Luis Ignacio. Universidad de Buenos Aires. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cruz, Pablo. No especifíca;
Fil: Cangas, Alicia. No especifíca;
Fil: González Rojas, Carmen. No especifíca;
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
description The association of sleep disruption with a higher vulnerability to COVID-19 infection is asubject of major clinical importance. In patients with pneumonia associated with COVID-19admitted to non-intensive care unit (NICU) several factors, like the disrupting influence ofrespiratory distress, medication, greater stress due to social isolation, and lack of appropriateexposure to environmental light can be instrumental to disrupt sleep / wake cycle. Thetherapeutic potential of melatonin to counteract the consequences of COVID-19 infection hasbeen advocated. Because of its wide-ranging effects as an antioxidant, anti-inflammatory, andimmunomodulatory compound, melatonin could be unique in impairing the consequences ofSARS-CoV-2 infection. Melatonin is also an effective chronobiotic agent to reverse the circadiandisruption of social isolation and to control delirium in severely affected patients. Properlyadministered, melatonin may restore the optimal circadian pattern of the sleep-wake cycle andimprove clinical condition in pneumonia associated with COVID-19 patients. The present reviewarticle discusses the importance of maintaining normal sleep and circadian rhythmicity in NICUpatients and provides preliminary data suggesting the efficacy of melatonin (9 mg/day) to reducelength of stay of pneumonia patients associated with COVID-19 in NICU.
publishDate 2021
dc.date.none.fl_str_mv 2021-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/134834
Brusco, Luis Ignacio; Cruz, Pablo; Cangas, Alicia; González Rojas, Carmen; Vigo, Daniel Eduardo; et al.; Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation; Open Journal Systems; Melatonin Research; 4; 1; 1-2021; 173-188
2641-0281
CONICET Digital
CONICET
url http://hdl.handle.net/11336/134834
identifier_str_mv Brusco, Luis Ignacio; Cruz, Pablo; Cangas, Alicia; González Rojas, Carmen; Vigo, Daniel Eduardo; et al.; Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation; Open Journal Systems; Melatonin Research; 4; 1; 1-2021; 173-188
2641-0281
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.32794/mr11250089
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Open Journal Systems
publisher.none.fl_str_mv Open Journal Systems
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613120905969664
score 13.070432

Publicaciones similares